Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: Results of a randomized trial

Breast Cancer Research and Treatment

Volumn 55, Issue 1, 1999, Pages 51-59

  Kloke, O ^a   Klaassen, U ^b   Oberhoff, C ^b   Hartwich, G ^b   Szanto, J ^b   Wolf, E ^b   Heckmann, M ^b   Huhn, R ^b   Stephan, L ^b   Schnepper, U ^b   Donsbach, G M ^b   Bechtel, C ^b   Rudolph, R ^b   Berke, A ^b   Borquez, D ^b   Hawig, I ^b   Hirche, H ^b   Schindler, A E ^b   Seeber, S ^b   Becher, R ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NONE

Author keywords

Chemotherapy; Endocrine maintenance therapy; Medroxyprogesterone acetate

Indexed keywords

EPIRUBICIN; IFOSFAMIDE; MEDROXYPROGESTERONE ACETATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBESITY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING; VISUAL IMPAIRMENT;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; GERMANY; HUMANS; IFOSFAMIDE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 0032839396     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006169012544     Document Type: Article

References (22)

1. 1. Veronesi U, Goldhirsch A, Yarnold J: Breast cancer. In: Peckham M, Pinedo H, Veronesi U (eds) Oxford Textbook of Oncology. Oxford University Press, Oxford, 1995, pp 1241-1292
2. 2. Honig SF: Treatment of metastatic disease. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Lippincott-Raven, Phildelphia, 1996, pp 669-734
3. 3. Becher R, Kloke O, Hayungs J, Hartwich G, Bartels H, Szanto J, Wolf E, Illiger HJ, Halabi S, Rieche K, Hering KG, Öhl S, DeDycker R, Huhn R, Fischedick AR, Höfeler H, Pielken HJ, Hawig I, Hirche H, Seeber S: Epirubicin and ifosfamide in metastatic breast cancer. Semin Oncol 23 (suppl 7): 28-33, 1996
4. 4. Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MHN, Byrne M, Harvey V, Gill G, Simpson J, Drummond R, Browne J, van Cooten R, Forbes JF (for the Australian-New Zealand Breast Cancer Trials Group): Improving the quality of life during chemotherapy for advanced cancer. N Engl J Med 317: 1490-1495, 1987
5. 5. Harris AL, Cantwell BMJ, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RGB: Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335: 186-190, 1990
6. 6. Muss HB, Case D, Richards F, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL, and the Piedmont Oncology Association: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325: 1342-1348, 1991
7. 7. Ejlertsen B, Pfeiffer P, Mouridsen HT, Rose C, Overgaard M, Sandberg E, Kristensen B: Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A: 527-531, 1993
8. 8. Gregory RK, Powles TJ, Chang JC, Ashley S: A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33: 2194-2197, 1997
9. 9. Gracia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R, Maillart P, Mauriac L, May-Levin F, Metz R, Namer M, Olivier JP, Commatau E, Pouillart P, Pujade-Lauraine E, Rouesse J, Serrou B, Vitse M, Zylberait D: Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat 24: 139-145, 1992
10. 10. Gundersen S, Hannisdal E, Lundgren S, Wist E (for the Norwegian Breast Cancer Study Group): Weekly doxorubicin with and without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer: A randomised study. Eur J Cancer 30: 1775-1778, 1994
11. 11. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
12. 12. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometric 31: 103-115, 1975
13. 13. Hayward JL, Carbone PP, Heuson JG, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289-1294, 1977
14. 14. George SL, Desu MM: Planning the size and duration of a clinical trial studying the time to some critical event. J Chron Dis 27: 15-24, 1974
15. 15. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35: 549-556, 1979
16. 16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
17. 17. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748, 1959
18. 18. Cox DR, Oakes D: Analysis of Survival Data. Chapman and Hall, London, 1984
19. 19. Zelen M: Theory and practice of clinical trials. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine. Lea & Febiger, Philadelphia, 1993, pp 340-360
20. 20. Robustelli Della Cuna G, Pellegrini A: Medroxyprogesterone acetate in combination with chemotherapy for advanced breast cancer: Updated results and criticisms. In: Pellegrini A, Robustelli Della Cuna G, Pannuti F, Pouillart P, Jonat W (eds) Role of Medoxyprogesterone in Endocrine-related Tumors. Raven Press, New York, 1984, pp 91-104
21. 21. Hürny C, Bernhard J, Joss R, Willems Y, Cavalli F, Kiser J, Brunner K, Favre S, Alberto P, Glaus A, Sena H, Schatzmann E, Ganz PA, Metzger U (for the Swiss Group for Clinical Cancer Research SAKK, Bern, Switzerland): Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer - a lesson from the real world. Ann Oncol 3: 825-831, 1992
22. 22. Stockler M, Wilcken N, Coates A: Chemotherapy for metastatic breast cancer - when is enough enough? Eur J Cancer 33: 2147-2148, 1997